Loading stock data…
CBLL
$20.15-0.22 (-1.08%)
CeriBell, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CBLL in the Healthcare sector is trading at $20.15. The stock is currently 17% below its 52-week high of $24.33, remaining 20.4% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why CBLL maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$20.15
Potential Upside
5%
Whystock Fair Value$21.16
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$797.59M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.81%
Volume
Today's trading volume
219,039
Recent News
Phibro Animal Health (PAHC) Q3 Earnings and Revenues Surpass Estimates
Phibro (PAHC) delivered earnings and revenue surprises of +5.92% and +6.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ceribell (CBLL) Rose 91% after Reporting Inline Financial Results
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) in the fourth quarter compared to a 1.22% return for the Russell 2000 Growth Index. In 2025, the strategy […]
CeriBell Conference: CFO Highlights 36% Revenue Growth, Expands EEG Platform to Pediatrics and Delirium
CeriBell (NASDAQ:CBLL) is seeking to accelerate adoption of its point-of-care EEG platform in U.S. hospitals while expanding into new patient populations and indications, Chief Financial Officer Scott Blumberg said at the 47th Annual Raymond James Institutional Investors Conference. Blumberg told i
CeriBell Highlights 2026 Growth Plan at TD Cowen: 25%-29% Guide, VA Ramp, Delirium Pilot
CeriBell (NASDAQ:CBLL) executives outlined the company’s 2026 priorities and growth drivers during a fireside chat at the 46th annual TD Cowen Healthcare Conference, emphasizing continued expansion in hospital adoption, upcoming pediatric and neonatal offerings, early plans for a delirium commercial
Cautious Guidance Offsets Solid Q4 for CeriBell, Inc. (CBLL), Says Canaccord
CeriBell, Inc. (NASDAQ:CBLL) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. CeriBell, Inc. (NASDAQ:CBLL) secures the twelfth place on our list of most promising stocks. TheFly reported on February 25 that Canaccord reduced its price target for CBLL from $30 to $28 and maintained a Buy rating on the stock. […]